Market revenue in 2024 | USD 12.3 million |
Market revenue in 2030 | USD 10.9 million |
Growth rate | -2.3% (CAGR from 2025 to 2030) |
Largest segment | Eylea |
Fastest growing segment | Vabysmo |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Eylea, Lucentis, Beovu, Vabysmo |
Key market players worldwide | Roche Holding AG ADR, Biogen Inc, Pfizer Inc, Amgen Inc, Bausch Health Companies Inc, Viatris Inc, Coherus BioSciences Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anti-vascular endothelial growth factor therapeutics market will help companies and investors design strategic landscapes.
Eylea was the largest segment with a revenue share of 58.54% in 2024. Horizon Databook has segmented the Kuwait anti-vascular endothelial growth factor therapeutics market based on eylea, lucentis, beovu, vabysmo covering the revenue growth of each sub-segment from 2018 to 2030.
In Kuwait, the anti-VEGF therapeutics market is gaining traction, primarily as a response to high diabetes prevalence, which has increased the incidence of diabetic eye diseases such as diabetic retinopathy and macular edema. As the government scales up healthcare spending, demand for advanced ophthalmic treatments is rising, particularly for those targeting retinal conditions.
The Ministry of Health’s collaborations with global pharmaceutical companies have expanded access to anti-VEGF therapies, while recently implemented healthcare reforms support efficient approvals of biosimilars. These measures, alongside high urbanization rates, are driving both awareness and adoption of antiVEGF treatments, making Kuwait an important market for both branded biologics and biosimilars in the region.
Horizon Databook provides a detailed overview of country-level data and insights on the Kuwait anti-vascular endothelial growth factor therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Kuwait anti-vascular endothelial growth factor therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account